Expert Point of View: Elisabeth Quoix, MD

Get Permission

The study discussant, Elisabeth Quoix, MD, of the University Hospitals of Strasbourg, France, said that this meta-analysis confirmed that platinum-based doublets remain the standard treatment in this setting. Benefit of platinum-based doublets over non–platinum-based chemotherapy is essentially due to cisplatin (only a trend was seen for carboplatin). However, in special populations (patients with performance status 2, elderly patients) a carboplatin-based doublet should be considered and is probably superior to single new agents.

Need for Meta-analyses

Furthermore, Dr. Quoix emphasized that the high number of meta-analyses performed in advanced NSCLC probably reflects the heterogeneity of patients included in randomized controlled trials (regarding age, performance status, and so forth), which lead to conflicting or at least inconclusive results. Thus, meta-analyses are required to answer important questions, but a good question is why repeated results of meta-analyses do not convince doctors to modify their clinical attitude, she noted. ■

Disclosure: Dr. Quoix reported no potential conflicts of interest.

Related Articles

Meta-analysis Slightly Favors Platinum-based First-line Treatment in Patients with Advanced NSCLC

Several meta-analyses conducted in the past have suggested that survival of patients with advanced non–small cell lung cancer (NSCLC) is improved if first-line chemotherapy includes platinum derivatives. Results from a new meta-analysis of randomized clinical trials show that platinum-based...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.